Arnauld Villers

Active 1989–2025

121
Papers
27,900
Citations
78
h-index
116
i10-index

Citations

Citations per year for Arnauld Villers1961: 1 citations1989: 2 citations1990: 3 citations1991: 4 citations1992: 16 citations1993: 40 citations1994: 26 citations1995: 39 citations1996: 32 citations1997: 25 citations1998: 32 citations1999: 20 citations2000: 16 citations2001: 29 citations2002: 16 citations2003: 17 citations2004: 9 citations2005: 12 citations2006: 18 citations2007: 30 citations2008: 33 citations2009: 74 citations2010: 150 citations2011: 165 citations2012: 237 citations2013: 291 citations2014: 274 citations2015: 266 citations2016: 258 citations2017: 205 citations2018: 276 citations2019: 775 citations2020: 787 citations2021: 719 citations2022: 634 citations2023: 449 citations2024: 822 citations2025: 308 citations2026: 13 citations1962–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,302 citing papers, 23.5% of this breakdownUnited Kingdom: 818 citing papers, 8.3% of this breakdownItaly: 657 citing papers, 6.7% of this breakdownGermany: 612 citing papers, 6.2% of this breakdownChina: 516 citing papers, 5.3% of this breakdownCanada: 499 citing papers, 5.1% of this breakdownFrance: 490 citing papers, 5% of this breakdownNetherlands: 490 citing papers, 5% of this breakdownAustralia: 280 citing papers, 2.9% of this breakdownSwitzerland: 252 citing papers, 2.6% of this breakdownSweden: 250 citing papers, 2.5% of this breakdownSpain: 233 citing papers, 2.4% of this breakdown
0%23.5%Other 24.5%

Fields

  • Medicine85%
  • Biochemistry, Genetics and Molecular Biology7.2%
  • Computer Science2.2%
  • Engineering2.1%
  • Immunology and Microbiology0.7%
  • Health Professions0.6%
  • Other2.2%

Topics

  • Prostate Cancer Diagnosis and Treatment22.8%
  • Prostate Cancer Treatment and Research19.5%
  • Urologic and reproductive health conditions3.6%
  • MRI in cancer diagnosis3.2%
  • Advanced Radiotherapy Techniques2.9%
  • Urinary Bladder and Prostate Research2.1%
  • Other45.9%

Coauthors

All papers

Open in search
  1. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clare Allen, Francesco Giganti, Alex Freeman, Stephen Morris, Shonit Punwani, Norman Williams, Chris Brew‐Graves, Jonathan J Deeks, Yemisi Takwoingi, Mark Emberton, Caroline M. Moore - New England Journal of Medicine 2018 cited by 3,016

  2. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 1,186

  3. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anssi Auvinen - European Urology 2019 cited by 698

  4. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 291

  5. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 299

  6. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2014 cited by 1,565

  7. Screening and Prostate-Cancer Mortality in a Randomized European Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 4,014

  8. A Novel Robotic System for Single-port Urologic Surgery: First Clinical Investigation

    Authors: , , , , , , - European Urology 2014 cited by 283

  9. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas J. Povsic, Michael Morse, Kenneth W. Mahaffey, Susan Halabi, Darryl P. Leong, Laurence Klotz, Neil Fleshner, G. Kenneth Jansz, Jonathan Giddens, R. Blair Egerdie, Joseph L. Chin, Joseph Zadra, Richard Casey, Jean Simard, Tamim Niazi, André‐Guy Martin, Marek Babjuk, Jaroslav Hájek, Jiří Klečka, Jiří Kubeš, Jan Schraml, Jitka Jakesova, J Vaňásek, Bohuslav Melichar, Heikki Seikkula, M. Abdiche, Marc Colombel, P. Debourdeau, G. Robert, Arnauld Villers, Guillaume Ploussard, Benjamin Pradère, F. Bruyère, Jean‐Luc Descotes, Idir Ouzaïd, Alexander Winter, Herbert Hanitzsch, H. Sperling, Ralf Eckert, Peter Hammerer, E. Stagge, F. Seseke, Silvio Szymula, Aristotelis Bamias, A. Thanos, Konstantinos Hatzimouratidis, Charalambos Mamoulakis, Haralabos P. Kalofonos, Elżbieta Oszukowska, Katarzyna Madziarska, Jacek Fijuth, Mateusz Obarzanowski, B. Yа. Alekseev, Vagif Atduev, Dmitri Pushkar, Evgeniy Veliev, A. V. Zyryаnov, С Б Петров, Evgeny Kopyltsov, Vadim Kozlov, Ladislav Macko, J. Dúbravický, Richard Polak, Obaidullah Mir, Marek Vargovcak, I. Minčík, J. Kliment, Frederico Gonçalves, J Mikuláš, Roman Sokol and 55 more - Circulation 2021 cited by 143

  10. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature

    Authors: , , , , , , , , , - European Urology 2015 cited by 786

  11. Prostate-Cancer Mortality at 11 Years of Follow-up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 1,241

  12. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2017 cited by 247

  13. Global Variation in Magnetic Resonance Imaging Quality of the Prostate

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolina Aulló González, Chau Hung Lee, Christian Wetterauer, Claudia Kesch, Daniel A. Adamo, Daniel Margolis, Daniel José López Ruiz, David Margel, Declan G. Murphy, Enrique Gómez‐Gómez, Felix K.‐H. Chun, Felix Preißer, Francis Thomas, Geert Villeirs, Giancarlo Marra, Gianluca Giannarini, Giorgio Brembilla, G. Robert, Guglielmo Manenti, Hannes Cash, Ingrid Potyka, Jan Philipp Radtke, Jeffrey J. Leow, Jens Theysohn, Jim C. Hu, Jingfei Ma, Lance A. Mynderse, Lars Boesen, Lars Budäus, Lars Schimmöller, Lee Alexander Grant, Luca Orecchia, Maarten de Rooij, Maneesh Ghei, Marco Gatti, Mariano Volpacchio, Markku H. Vaarala, Martina Pecoraro, Massimo Imbriaco, Matthias Roethke, M.A. Rodríguez Cabello, Nazar Miguel, Paras Singh, Nicola Muirhead, Peter Ka‐Fung Chiu, Philip Ryan, Philippe Puech, Pierre Mozer, Pieter De Visschere, Públio César Cavalcante Viana, Raphaële Renard Penna, Réka Novotta, Renato Cuocolo, Richard O’Sullivan, Rossano Girometti, Sangeet Ghai, Scott E. Eggener, Tharakeswara Bathala, Tho Pham, Tristan Barrett, Valeria Panebianco, Vibeke Løgager, Vinayak Wagaskar, Yaara Ber, Y. Lebras - Radiology 2023 cited by 56

  14. Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2013 cited by 451

  15. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

    Authors: , , , , , , , , , , - The Lancet Oncology 2016 cited by 283

  16. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , R. Valdagni, Antoinette S. Perry, Jonas Hugosson, J. Rubio‐Briones, Anders Bjartell, Lukas Hefermehl, Lee Lui Shiong, Mark Frydenberg, Yoshiyuki Kakehi, Byung Ha Chung, Theodorus van der Kwast, Henk Obbink, Wim van der Linden, Tim Hulsen, Cees de Jonge, Mike Kattan, Xinge Ji, Kenneth Muir, Artitaya Lophatananon, Michael Fahey, Ewout W. Steyerberg, Daan Nieboer, Liying Zhang, Ewout W. Steyerberg, Daan Nieboer, A. Santa Olalla, Kerri Beckmann, Brian T. Denton, Andrew Hayen, Paul C. Boutros, Wei Guo, Nicole Benfante, Janet E. Cowan, Dattatraya Patil, Emily Tolosa, Tae-Kyung Kim, Alexandre Mamedov, Vincent La Pointe, Trafford Crump, Jenna Kimberly-Duffell, Aida Santaolalla, Daan Nieboer, Jonathan Olivier, T. Rancati, Helén Ahlgren, Juanma Mascarós, Annica Löfgren, Kurt Lehmann, Catherine Han Lin, Hiromi Hirama, Kwang Suk Lee, Guido Jenster, Anssi Auvinen, Anders Bjartell, Masoom A. Haider, Kees van Bochove, Ballentine Carter, Sam Gledhill, Mark Buzza, Chris H. Bangma, Monique J. Roobol, Sophie Bruinsma, Jozien Helleman - European Urology 2018 cited by 93

  17. Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2010 cited by 728

  18. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review

    Authors: , , , , , , - European Urology 2016 cited by 297

  19. Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 124

  20. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shahrokh F. Shariat, Nicola Schieda, Clare M. Tempany, Barış Türkbey, Massimo Valério, Arnauld Villers, Jochen Walz, Tristan Barrett, Francesco Giganti, Caroline M. Moore - European Urology 2024 cited by 58

  21. Quality-of-Life Effects of Prostate-Specific Antigen Screening

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 425

  22. Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data

    Authors: , , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2014 cited by 161

  23. Surveillance after prostate focal therapy

    Authors: , , , , , , , , , , , - World Journal of Urology 2018 cited by 96

  24. Predictive factors of urinary incontinence after holmium laser enucleation of the prostate: a multicentric evaluation

    Authors: , , , , , , , , , , , , - World Journal of Urology 2020 cited by 70